| Similar Articles |
|---|
 |
The Motley Fool
February 11, 2008
Brian Lawler |
No Fire Fueling Flamel's Top Drug Flamel Technologies had a rough 2007; and with only one drug determining its near-term success, investors should be cautious of this drugmaker.   |
The Motley Fool
March 5, 2008
Brian Lawler |
Flamel in a Nutshell After a choppy year, Flamel says there are plenty of new possibilities in its pipeline. |
The Motley Fool
October 25, 2007
Brian Lawler |
Flamel Gets Upbeat News About Coreg Flamel Technologies is earning more than had been calculated from its lead drug, but the company still isn't profitable. Investors, take note. |
The Motley Fool
August 8, 2008
Brian Lawler |
Flamel Tries to Get It in Gear Flamel has done a good job of reducing its cash burn, allowing it to buy some time to work on the compounds in its pipeline. |
The Motley Fool
May 15, 2008
Brian Lawler |
What's Cooking at Flamel? The drugmaker makes finding partners to help pay for its hepatitis C and diabetes compounds a top priority. |
The Motley Fool
November 2, 2007
Brian Lawler |
Flamel Plays Close to the Vest With only one sustainable source of revenue, the drug developer tries to curtail spending and get new compounds into the pipeline. Investors, take note. |
The Motley Fool
August 27, 2007
Rich Duprey |
Flamel Falls Out of Compliance Market lashes out after a patient-compliance study shows that its only drug offers no better solution. Flamel has always been a risky investment, and that hasn't changed. |
The Motley Fool
May 14, 2007
Brian Lawler |
Just the Beginning for Flamel? The drug developer released first-quarter financial results and updated investors on the progress of its newly marketed Coreg CR compound. Investors, take note. |
The Motley Fool
October 26, 2007
Brian Lawler |
Another Prospect for Flamel The drug developer's good week continues with favorable news about a treatment for hepatitis C. Investors, take note. |
The Motley Fool
December 18, 2006
Brian Lawler |
Nice: Flamel's Drug Approval With so much pessimism and internal hullabaloo, there weren't many investors willing to stick with Flamel, but those who did have been rewarded nicely. |
The Motley Fool
July 26, 2007
Brian Lawler |
Flamel Gets Stomped by GSK Shares of Flamel fall as its partner doesn't focus on marketing its lead drug. |
The Motley Fool
September 14, 2007
Brian Lawler |
Is Flamel Catching On? Flamel Technologies announces a deal with Wyeth to develop an improved formulation of a drug, but the financials, and details, remain secret. |
The Motley Fool
August 3, 2007
Brian Lawler |
Flamel Cooked When a drugmaker's future is highly dependent on one product, shares are bound to take a hit if that product isn't living up to expectations. Such was the case with Flamel Technologies. |
The Motley Fool
February 26, 2010
Brian Orelli |
A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus. |
The Motley Fool
October 25, 2005
Jason Mac Gurn |
Visualizing Value for Flamel Those interested in the long-term potential of this biotech's business should be searching for signs that its technological potential will evolve to provide value for shareholders. |
The Motley Fool
August 24, 2007
Brian Lawler |
Flamel Under Fire Stocks fall when study fails to show drug's superiority. Investors, take note. |
The Motley Fool
April 28, 2008
Brian Lawler |
Glaxo Getting By Weakening currency barely redeems the pharmaceutical's Q1 numbers. |
The Motley Fool
November 26, 2007
Brian Lawler |
Glaxo Goes Holiday Shopping The pharmaceutical giant snaps up another acquisition, privately held Reliant Pharmaceuticals, for $1.65 billion in cash, one of the largest pharma deals of the year. |
The Motley Fool
April 28, 2005
Stephen D. Simpson |
Glaxo Works to Stay on Track With FDA issues near resolution, Glaxo should continue its respectable growth trajectory. Investors looking at the pharmaceutical space would do well to at least consider this stock. |
The Motley Fool
March 17, 2011
Brian Orelli |
Eat or Be Eaten? Perhaps Both. Oft-rumored takeout target Human Genome Sciences goes shopping. |
The Motley Fool
February 4, 2010
Brian Orelli |
Glaxo Brings Home the Bacon Swine flu gives GlaxoSmithKline the boost, but how long will it last? |
The Motley Fool
November 15, 2007
Brian Lawler |
Flamel Now Part of Wacky Lawsuit Hijinks Multiple class action shareholder lawsuits targeting Flamel Technologies are announced, following a failed study of the company's lead drug. |
The Motley Fool
September 26, 2007
Brian Orelli |
4 Platform Drugmakers to Watch Platform drugmakers have the potential to develop multiple drugs for a company. Let's take a look at four companies with good prospects: Abraxis BioScience... DURECT... Halozyme... Flamel Technologies... |
The Motley Fool
October 29, 2004
W.D. Crotty |
Future Looking Up for Flamel As the nanotech/biotech company earns a profit -- keep an eye on two drugs in phase 3 trials. |
The Motley Fool
July 30, 2004
W.D. Crotty |
This Nanotech Deserves Respect While the stock recently hit some potholes, Flamel still looks good for the future. |
The Motley Fool
June 6, 2005
Rich Duprey |
Flamel Inflames Passions The nanotech firm faces a fiery shareholder fight. Is Flamel doing enough to promote its medical technologies? Management says yes, but shareholders disagree. Here's a survey of the battlefield. |
The Motley Fool
September 27, 2005
Jack Uldrich |
A Ray of Hope for Flamel? New hepatitis C treatment offers a ray of hope to the ailing nanotech company. Unfortunately, this news does not guarantee sunnier days ahead. |
The Motley Fool
June 15, 2005
Charly Travers |
Flamel's CEO Must Go Because the biotech firm has disappointed, investors have understandably not rewarded its lousy results. Flamel's shareholders must vote to remove a management road block to the company's success. |
The Motley Fool
February 28, 2008
Brian Lawler |
Too Much Hope in Human Genome Shares Human Genome announces its guidance for 2008. Investors, take note. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
December 21, 2007
Brian Lawler |
Flamel Wheeling and Dealing Flamel announces very few details about it's latest deal, this time with German drugmaker Merck KGaA. |
The Motley Fool
November 9, 2006
Brian Lawler |
The Best Blue Chip for 2007: GlaxoSmithKline Here's a blue-chip pharma stock for your portfolio. |
The Motley Fool
July 28, 2005
Stephen D. Simpson |
Glaxo Keeps It Going Despite missing sales from the depression franchise, Glaxo managed to post respectable quarterly results. |
The Motley Fool
March 4, 2005
Rich Duprey |
Flamel Flames Out Again Nanotech regains rights to herpes treatment as partnership with pharma Biovail fails. |
The Motley Fool
August 2, 2007
Brian Lawler |
Human Genome Advances Human Genome Sciences updates investors on what to expect. The past quarter has been full of developments on their two lead drugs. Phase 3 studies for both are currently under way. |
The Motley Fool
February 3, 2011
Owain Bennallack |
Glaxo Sweetens a Bitter Pill The drugmaker reports a loss, but resumes share buybacks. |
The Motley Fool
February 8, 2006
Stephen D. Simpson |
Glaxo: Healthy Drugmaker Glaxo combines a huge sales force, a rich pipeline, and solid returns on capital. This company should get a thorough look from anyone putting new money into the pharma space. |
The Motley Fool
September 20, 2004
Wherrett & Yelovich |
Flamel Shot Down The company's nano product loses some of its shine. The stock fell more than 25% after Bristol-Myers Squibb pulled out of its partnership to develop Basulin. |
The Motley Fool
February 14, 2005
Stephen D. Simpson |
Glaxo Stays Above the Fray The British drugmaker looks to regain momentum this year. Investors who are comfortable with the general industry risks and are looking for a relatively "clean" pharmaceutical company should do some research on Glaxo shares. |
The Motley Fool
December 17, 2008
Brian Orelli |
A Super-Cheap Call Option GlaxoSmithKline announces it's partnering up with tiny Dynavax Technologies to develop up to four drugs for autoimmune and inflammatory diseases. The pay-if-the-drug-works scheme should pay off. |
The Motley Fool
August 30, 2007
Brian Lawler |
Human Genome Steps Forward Human Genome Sciences investors got good news as the drugmaker took a quicker-than-expected step in its journey to get its lead drug, hepatitis C treatment Albuferon, on the path to FDA approval. |
The Motley Fool
February 8, 2008
Brian Lawler |
Hold on to GlaxoSmithKline This might be a tough year for the big pharma company, but its pipeline makes it a keeper. |
The Motley Fool
April 16, 2009
Brian Orelli |
2 Virus Killers Are Better Than 1 Glaxo brings Pfizer under its HIV wing. |
The Motley Fool
April 17, 2008
Brian Orelli |
Headache Over for Pozen and Glaxo? The duo's FDA headache regarding their migraine drug is over, but a new one is about to begin. |
The Motley Fool
October 23, 2008
Brian Orelli |
Glaxo to Competitors: You're Cheaper Than We Are This big pharma has cash and it plans to use it. |
The Motley Fool
July 8, 2004
W.D. Crotty |
From Flameout to Bargain Despite its stock decline, there's a lot to like about French biopharmaceutical Flamel. |
The Motley Fool
June 14, 2005
Bill Mann |
It's Time for a Change at Flamel A dissident shareholder believes that the French medical tech company's management needs shaking up. Reluctantly, we agree. |
BusinessWeek
March 6, 2006
Gene G. Marcial |
Why Glaxo Looks More Robust Big pharma, besieged by generic rivals, is hardly a Street favorite. But GlaxoSmithKline may be an exception. |
The Motley Fool
October 28, 2004
Bill Mann |
Glaxo's Mild Depression The British drug maker sees increased generic competition for its anti-depressant drugs. Total constant currency sales slipped to $7.7 billion in the current quarter from $8.5 billion last year. |
The Motley Fool
November 24, 2009
Brian Orelli |
4 Platform Drugmakers to Invest In Elan ... Alkermes... Flamel Technologies... etc. |
